Sign In
Buy MCK
$763.91
+18.79 (+2.52%)
At Close: Jun 23, 2026
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
10:06am, Wednesday, 14'th May 2025
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson Corporation (MCK) CFO Britt Vitalone Hosts BofA Securities 2025 Healthcare Conference (Transcript)
03:37pm, Tuesday, 13'th May 2025
McKesson Corporation (NYSE:MCK ) BofA Securities 2025 Healthcare Conference May 13, 2025 11:00 AM ET Company Participants Britt Vitalone - Chief Financial Officer Conference Call Participants Allen Lu
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term
10:55am, Monday, 12'th May 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why McKesson Stock Bumped Modestly Higher Today
05:03pm, Friday, 09'th May 2025
Storied healthcare supplies company McKesson (MCK 0.34%) was a slight outperformer on the stock exchange Friday, as investors considered its results for its fourth quarter of fiscal 2025. They liked,
McKesson: Spinoff Of Medical-Surgical Solutions Is A Positive, Strong Buy
12:49pm, Friday, 09'th May 2025
I reiterate a Strong Buy rating on McKesson Corporation with a fair value of $828 per share, driven by robust growth in the oncology and biopharma sectors. McKesson posted 19% revenue growth and 63.8%
MCK Stock Up on Q4 Earnings Beat & Potential Surgical Biz Spin-Off
10:30am, Friday, 09'th May 2025
McKesson's fourth-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
McKesson Corporation (MCK) Q4 2025 Earnings Call Transcript
08:08pm, Thursday, 08'th May 2025
McKesson Corporation (NYSE:MCK ) Q4 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Brian Tyler - Chief Executive Officer Britt Vitalone - Chief Financial Officer Jeni Doming
Here's What Key Metrics Tell Us About McKesson (MCK) Q4 Earnings
07:05pm, Thursday, 08'th May 2025
While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare t
McKesson (MCK) Tops Q4 Earnings Estimates
06:35pm, Thursday, 08'th May 2025
McKesson (MCK) came out with quarterly earnings of $10.12 per share, beating the Zacks Consensus Estimate of $9.81 per share. This compares to earnings of $6.18 per share a year ago.
McKesson to spin off surgical supplies unit, forecasts strong annual profit
05:45pm, Thursday, 08'th May 2025
McKesson forecast fiscal 2026 profit largely above estimates on Thursday and said it is planning to spin off its medical-surgical solutions unit into an independent company to focus on its core drug d
McKesson to Spin Off Medical-Surgical Company
05:40pm, Thursday, 08'th May 2025
The pharmaceutical distributor said the new company would be a differentiated medical surgical supply and solutions business.
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2025 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at inve
How To Earn $500 A Month From McKesson Stock Ahead Of Q4 Earnings
08:48am, Thursday, 08'th May 2025
McKesson Corporation MCK will release its fourth-quarter financial results after the closing bell on Thursday.
Brokers Suggest Investing in McKesson (MCK): Read This Before Placing a Bet
10:36am, Tuesday, 06'th May 2025
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
MCK Stock Up 24% YTD: Should You Buy, Hold or Sell Before Q4 Earnings?
08:15am, Tuesday, 06'th May 2025
McKesson's fourth-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
